Compare Davita Inc (DVA) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs US Bancorp — how do they compare? Davita Inc trades at $232.01 (market cap $15.12B), while US Bancorp trades at $62.98 (market cap $97.11B). The key difference: US Bancorp is far larger — about 6.4× Davita Inc's market cap, and US Bancorp pays a 3.34% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | USB | |
|---|---|---|
Market Cap | $15.12B | $97.11B |
Sector | Health | Financials |
52-Week High | $235.71 | $62.89 |
52-Week Low | $103.87 | $43.94 |
Enterprise Value | $27.67B | — |
Dividend Yield | — | 3.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
U.S. Bancorp (USB) trades at $62.34, near the lower end of analyst targets, with a modest daily decline. The stock shows bullish technical signals from moving averages and has consistently beaten earnings estimates in recent quarters. Revenue and net income have grown steadily, with 2025 net income reaching $7.57 billion. Recent news highlights new small business payment tools and positive earnings expectations for Q2 2026.
The outlook is supported by strong profitability and a favorable analyst consensus, but risks include elevated debt levels and interest rate sensitivity. The stock offers value with a P/E of 13.07 and a dividend, though net cash flow remains negative. Upside to the $67 consensus target depends on continued earnings execution amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
